LAG3 and neoplasm: This study concluded that the poor efficacy of ACT was associated with a high frequency of markers associated with effector T-cell dysfunction, including PD-1 and lymphocyte-activation gene 3 (LAG3) expressed on TILs, in addition to substantial PD-L1 expression in the tumour tissue from which the TILs were harvested [70].